期刊
SEMINARS IN IMMUNOPATHOLOGY
卷 41, 期 4, 页码 461-475出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00281-019-00738-3
关键词
Bariatric surgery; Gut microbiota; Inflammation; Type 2 diabetes; Obesity; Microbiome
资金
- European Union [HEALTH-F4-2012-305312]
- French national program Investissement d'Avenir FORCE, the Metagenopolis grant [ANR-11-DPBS-0001, ANR-10-IAHU-05]
- National Agency of Research ANR-OB MAIT, CAPTOR
- INSERM
- Agence Nationale de la Recherche (ANR) [ANR-11-DPBS-0001] Funding Source: Agence Nationale de la Recherche (ANR)
Obesity is a chronic low-grade inflammatory disease (both at the systemic and adipose tissue level) that continues to rise worldwide. It is associated with an abundance of comorbidities, including type 2 diabetes (T2D). Bariatric surgery, which induces modifications of the intestinal tract, is to date the most successful treatment for obesity. Its use has dramatically increased in number as it enables both weight reduction and metabolic improvements, with 60% of patients even achieving diabetes remission. Several mechanisms are actually demonstrated to be involved in those clinical improvements. Importantly, both obesity and T2D share many phenotypic characteristics, including increased systemic and adipose tissue inflammation, as well as gut microbiota dysbiosis. These characteristics are deeply modulated after bariatric surgery. This review will address the host metabolic changes observed after bariatric surgery, focusing on the induced gut architectural changes, as well as on the modifications of the inflammatory tone and the gut microbiota.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据